SVP, Head of Manufacturing
Dr. Rook has over 20 years of academic and industry experience in molecular biology, diagnostics development and cell and gene therapy manufacturing.
Prior to joining Sigilon, Dr. Rook was VP and Head of the Gene Editing & Novel Modalities Business of MilliporeSigma. There she led a team developing and providing tools and services for cell and gene therapies from discovery to manufacturing. Those tools included genome editing research tools, cell model systems and a platform of scalable, disposable production solutions for the manufacture of cell & gene based therapies as well as contract manufacturing services for viral vector production. Dr. Rook also previously held a variety of senior roles at MilliporeSigma including Head of Novel Therapies, Director of Stem Cell Bioprocessing and Head of Upstream and Sensor Technologies. Prior to joining MilliporeSigma, Dr. Rook worked in the clinical diagnostics field at Quest Diagnostics and Variagenics.
Dr. Rook received her Ph.D. in biochemistry from MIT and holds a B.S. in chemistry from Texas A&M University. She pursued post-doctoral studies in neuroscience as a Lefler Fellow at Harvard Medical School’s Center for Neurologic Diseases.